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Complementary isonitrile-based multicomponent
reactions for the synthesis of diversiﬁed cytotoxic
hemiasterlin analogues†
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Ernest Hamel,c Fiorella Meneghetti,d Giulia Rainoldi,a Mattia Stucchi,a
Alessandro Sacchetti,e Alessandra Silvani*a and Giampietro Viola*b
A small family of structural analogues of the antimitotic tripeptides, hemiasterlins, have been designed
and synthesized as potential inhibitors of tubulin polymerization. The eﬀectiveness of a multicomponent
approach was fully demonstrated by applying complementary versions of the isocyanide-based Ugi reac-
tion. Compounds strictly related to the lead natural products, as well as more extensively modiﬁed ana-
logues, have been synthesized in a concise and convergent manner. In some cases, biological evaluation
provided evidence for strong cytotoxic activity (six human tumor cell lines) and for potent inhibition of
tubulin polymerization.
Introduction
Multicomponent reactions (MCRs) are convergent chemical
processes that involve the one pot condensation of more than
two reactants to form a product that incorporates most of each
reagent, containing ideally all atoms. In addition to generating
structural complexity with greater atom economy, they usually
also oﬀer the advantage of simplicity and synthetic eﬃciency
over conventional chemical reactions.1 In particular, isonitrile-
based MCRs (IMCRs) are widely applied in diversity-oriented
synthetic strategies, due to the considerable ability of iso-
cyanides to undergo α-addition with electrophiles and nucleo-
philes and due to the various possibilities to exploit the
diﬀerent secondary reactions of the obtained α-adducts.
Among IMCRs, the Ugi reaction has undergone developments
over the years, and various modifications of the classic proto-
col have been used successfully. As a consequence, more than
linear, peptide-like adducts can be obtained by the introduc-
tion of unusual building blocks, by transformation of the MCR
products using post-condensation reactions or by performing
intramolecular IMCRs with bifunctional inputs.2
Nevertheless, with regard to the target-oriented synthesis of
natural products or their derivatives, the rational design of
practical and versatile approaches employing MCRs, and in
particular the Ugi reaction and its modifications, remained,
until recently, a largely unexplored area of chemical research.3
As a result of our interest in the MCR-based approach to con-
formationally constrained peptidomimetics,4 in this work we
show the use of complementary Ugi-type reactions for the syn-
thesis of a small family of cytotoxic hemiasterlin analogues.
Hemiasterlins are a family of natural tripeptides, discovered
and isolated from the South African marine sponge Hemia-
strella minor some years ago.5 The most active members of the
family show cytotoxicity in the nanomolar range and are highly
potent inhibitors of microtubule polymerization, binding in the
vinca domain of tubulin.6 Relative to other known antimitotic
agents, hemiasterlins possess an attractive combination of
structural simplicity and potent antimitotic activity, which
makes them ideal targets for synthetic modification.7
Recently, synthetic analogues of hemiasterlin 1 (Fig. 1),
namely taltobulin (HTI-286) 2 and the closely related 3,8,9
wherein aryl groups replace the indol-3-yl substituent, and the
piperidine-based E7974 4 10 advanced into clinical trials, due
to their more potent in vivo cytotoxicity and antimitotic
activity. Moreover, unlike taxanes and vincas, such synthetic
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derivatives are poor substrates for P-glycoprotein drug trans-
porters and maintain toxicity towards cell lines with high
expression of multidrug resistant (MDR) eﬄux pumps.
Further, since 4 binds predominantly to the α-subunit of the
tubulin, with minor binding to the β-subunit, it oﬀers signifi-
cant promise of activity in taxane-resistant tumor types, regard-
less of whether the mechanism driving resistance is based on
P-glycoprotein or tubulin mutations.11
Hemiasterlins and their derivatives contain three highly
modified amino acids (A, B and C segments, see Fig. 1) and
their successful synthesis has always relied on amide bond
synthesis in a sterically challenged environment.12 This
approach has prevented more extensive structural modifi-
cations, for instance at the central (L)-valine or (L)-tert-leucine
amino acid residue.
Since the Ugi reaction and its modifications are less sensi-
tive to steric hindrance than peptide coupling, we envisioned
that a multicomponent strategy could be suitable for the gene-
ration of a wide range of hemiasterlin derivatives, also includ-
ing non-peptidic analogues. By means of a Ugi four-
component reaction (U-4CR), we achieved the synthesis of 5
(Fig. 2), a compound closely related to taltobulin, in which we
employed (L)-valine in the place of (L)-tert-leucine, as it rep-
resents a variation that could allow substantial bioequivalence.
By the same approach, we achieved also the unprecedented
indole-based analogue 6. Applying a Ugi-like three-component
reaction (U-like-3CR), oxazole-based compounds 7–9 could be
easily obtained. To the best of our knowledge, these com-
pounds represent the first example of hemiasterlin analogues
with major modifications of the central B core. Lastly, a Ugi–
Joullié three-component reaction (U-J-3CR) allowed us to prove
the applicability of the multicomponent approach for the syn-
thesis of piperidine-based compounds, such as 10–12, closely
related to E7974.
Results and discussion
The aldehyde components 13–16, which were necessary in the
U-4CR and U-like-3CR strategies, were prepared as described
in Scheme 1. The syntheses relied on an allylpalladium-cata-
lyzed α-arylation of isobutyraldehyde with an appropriate aryl
or heteroaryl bromide, in the presence of catalytic Q-phos,13
cleanly aﬀording the desired aldehydes in yields up to 75%.
Alternative palladium-catalyzed protocols, based on palladium
diacetate as the catalyst,14 or involving vinyl acetates as coup-
ling components,15 proved to be less eﬀective.
Many synthetic procedures are reported for the preparation
of isocyanides from α-amino acid ester hydrochlorides. In
order to achieve the enantiomerically pure α-isocyanoacetate
component 17 (Scheme 2), we selected a two-step sequence,
involving formylation of the precursor by reaction with tri-
methyl orthoformate under neat conditions, followed by de-
hydration of the obtained α-N-formylamino acid methyl ester,
using triphosgene as a mild dehydrating agent and N-methyl-
morpholine as the base.16 Trifluoroacetic acid and methyl-
amine were chosen as the suitable carboxylic acid and amine
for the U-4CR process.
To preserve the optical purity of the isocyanoacetate, the
Ugi reactions employing aldehydes 13 or 14 as carbonyl com-
Fig. 1 Tubulin polymerization inhibitors: natural hemiasterlins and syn-
thetic analogues.
Fig. 2 Structures of hemiasterlin analogues 5–12.
Scheme 1 Synthesis of aldehyde components 13–16. Reagents and
conditions: (a) isobutyraldehyde, [Pd(η3-allyl)Cl]2, Q-phos, Cs2CO3, THF,
reﬂux (13: 75%; 14: 57%; 15: 50%; 16: 46%).
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ponents were conducted after a precondensation time of 2 h
between the aldehyde and methylamine, in the presence of
MgSO4 used as the dehydrating promoter.
17 Ugi compounds
18 and 19 were obtained in good overall yields (63% for 18,
75% for 19), both as 1 : 1 diastereoisomeric mixtures, which
could be easily separated by flash chromatography (FC).
Relying on a valuable literature suggestion,18 the stereo-
chemistry of both compounds 18 and 19 was postulated by
NMR, and in particular performing the NOESY experiment on
the separated a and b diastereoisomers. Besides, with the aim
to unambiguously confirm the stereochemistry of these inter-
mediates, we performed X-ray diﬀraction analysis on com-
pound 18b, for which good diﬀracting single crystals were
isolated from a methanol solution. The crystallographic struc-
ture of 18b disclosed an (R,S)-configuration (Fig. 3), leading us
to select diastereoisomers 18a and 19a for continuing the syn-
thesis, as the stereochemistry reported for potent taltobulin
derivatives is (S,S,S).
To complete the synthesis, methyl esters 18a and 19a were
carefully converted into the corresponding acids under mild
basic conditions, with the preservation of the trifluoroacetamide
functional group, and then condensed with the known amino
ester fragment 20,20 in acceptable yields using HTBU and DIPEA.
From intermediates 21 and 22, the final compounds 5 and 6
were eventually recovered as amino acids by basic hydrolysis of
both the ethyl ester and the trifluoroacetamide group (Scheme 3).
With the aim of evaluating more extensively modified ana-
logues, even compounds lacking amide bonds, we looked at a
U-like-3CR and pursued the synthesis of oxazole-based com-
pounds 7–9, as depicted in Scheme 4. In this case, the key
intermediate is the α-isocyanoacetamide 23. Compared with
α-isocyanoacetates, α-isocyanoacetamides are much more con-
figurationally stable. They show a higher Lewis basicity of the
amide oxygen compared with that of the corresponding esters,
and this should kinetically favor the cyclization step with the
irreversible formation of the oxazole ring.21 Isocyanopeptide
23 was eﬃciently prepared starting from amine 24,22 through
intermediate formation of formamide 25 and subsequent
dehydration using diphosgene at −30 °C,23 as depicted in
Scheme 5. By stirring compound 23 with aldehydes 13, 15 or
16 in the presence of methylamine and MgSO4, we easily
obtained the final compounds 7–9, in satisfactory yields as an
inseparable 1 : 1 to 1.5 : 1 mixture of diastereoisomers. Since
for such extensively modified scaﬀolds the preliminary indi-
cation of activity can be considered the main goal, we per-
formed the biological evaluation on the diastereoisomeric
mixture (see below).
In order to exploit the multicomponent strategy for the syn-
thesis of piperidine-based E7974 analogues, we relied on the
Scheme 2 First multicomponent approach: the 4C-Ugi reaction. Reagents and conditions: (a) MeOH, MgSO4, rt (18a: 32%; 18b: 31%; 19a: 37%;
19b: 38%).
Fig. 3 ORTEP19 view of compound 18b, anti (R,S), and the relative
atom-numbering scheme (thermal ellipsoids at 40% probability).
Scheme 3 Synthesis of analogues 5 and 6. Reagents and conditions: (a)
LiOH, 50% aq. MeOH, rt; then (b) compound 20, HBTU, DIPEA, CH2Cl2,
rt (21: overall 58%; 22: overall 52%). (c) LiOH, 50% aq. MeOH, 60 °C (5:
76%; 6: 65%).
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U-J-3CR, a modification of the Ugi protocol involving the use
of cyclic imines and resulting in the synthesis of α-substituted
nitrogen heterocycles. Being aware of the reported risk of iso-
cyanoacetate epimerization related to the manner in which the
cyclic imine was prepared, we followed the protocol of indu-
cing a reversible trimerization of Δ1-piperideine, yielding cryst-
alline and easily isolable tripiperideine 26, as the starting
component. Carrying out the multicomponent reaction of tri-
piperideine, isocyanoacetate 17 and 5-pentenoic acid as the
acid component, we obtained the expected peptide 27 in good
yield, as a 1 : 1 inseparable diastereoisomeric mixture. Unfortu-
nately, this mixture could not be resolved at any stage of the
synthesis of the final compounds 11 and 12. In our approach,
the 5-pentenoic acid was chosen because the pentenoyl moiety
can be selectively removed by iodolactonization24 after the
multicomponent reaction and the resulting secondary amine
could be functionalized in various ways. Once the NH piper-
idine derivative 28 was synthesized, we looked at the reductive
amination as a route to install selected lipophilic moieties on
the piperidine ring. Therefore, after temporary Boc protection
of the piperidine secondary nitrogen to give 29 and sub-
sequent methylester hydrolysis and amide coupling with frag-
ment 20, we easily synthesized compound 10. From 10, Boc
deprotection gave the key intermediate 30. Reductive amin-
ation with acetone or cyclohexenone, using sodium triacetoxy-
borohydride and acetic acid, aﬀorded, respectively, the final
compounds 11 and 12 (Scheme 6).
Compounds 5–12 were evaluated in vitro for their cytotoxic
activity against a panel of six human tumor cell lines, and the
results are summarized in Table 1. Two of the analogues syn-
Scheme 5 Synthesis of the isocyanopeptide 23. Reagents and con-
ditions: (a) acetic formic anhydride, CH2Cl2, 0 °C to rt (25: quant. yield).
(b) N-methylmorpholine, diphosgene, THF, −30 °C to 0 °C (23: 80%).
Scheme 6 Third multicomponent approach: the 3C-Ugi–Joullié reaction. Synthesis of analogues 10–12. Reagents and conditions: (a) MeOH, rt
(27: 46%). (b) Iodine, aq. Na2S2O3, THF/H2O, rt (28: 85%). (c) (Boc)2O, CH2Cl2, rt (29: 92%). (d) LiOH, 50% aq. MeOH, rt; then (e) compound 20,
HBTU, DIPEA, CH2Cl2, rt (10: overall 47%). (f ) 50% TFA in CH2Cl2, rt (30: quant. yield). (g) Acetone, Na(OAc)3BH, AcOH, CH2Cl2, rt (11: quant. yield).
(h) Cyclohexenone, Na(OAc)3BH, AcOH, CH2Cl2, rt (12: quant. yield).
Scheme 4 Second multicomponent approach: the 3C-Ugi-like reac-
tion. Synthesis of analogues 7–9. Reagents and conditions: (a) MeOH,
MgSO4, rt (7: 51%; 8: 68%; 9: 64%).
Table 1 In vitro cell growth inhibitory eﬀects
Compd
GI50
a (nM)
HT-29 HeLa MCF-7 Jurkat HL-60 RS4;11
HTI-286 (2) 0.4 ± 0.05 0.3 ± 0.06 2.0 ± 0.6 0.2 ± 0.08 0.4 ± 0.1 0.3 ± 0.1
5 3000 ± 356 700 ± 259 3750 ± 943 176.7 ± 28.5 34.3 ± 5.6 430 ± 224
6 8.0 ± 2.4 11.2 ± 0.5 7.3 ± 1.7 0.8 ± 0.1 1.1 ± 0.1 2.3 ± 0.3
7 12 580 ± 738 21 300 ± 2979 16 800 ± 4217 2333 ± 120 3067 ± 120 2967 ± 418
8 23 500 ± 512 10 580 ± 5203 22 300 ± 1250 2441 ± 203 923 ± 79.3 2000 ± 600
9 4700 ± 711 8533 ± 654 8300 ± 1525 2433 ± 296 3800 ± 833 6833 ± 917
10 36 433 ± 2882 13 333 ± 4826 13 956 ± 6233 4400 ± 458 10 166 ± 1524 405 ± 45
11 4.2 ± 1.1 0.9 ± 0.3 25.3 ± 5.1 0.9 ± 0.2 0.8 ± 0.4 0.9 ± 0.4
12 18 780 ± 7486 22 760 ± 1311 17 160 ± 1513 223.3 ± 18.6 320 ± 35.1 125.3 ± 33
aGI50 = compound concentration required to inhibit tumor cell growth by 50%. Data are presented as the mean ± SE (Standard Error) from the
dose–response curves of at least three independent experiments.
Paper Organic & Biomolecular Chemistry
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thesized during this work, namely compounds 6 and 11, pos-
sessed cytotoxicity against all lines, though being 10-fold less
active compared to the model compound HTI-286. The other
compounds showed modest (compound 5) activity or were
practically devoid of any significant activity, having GI50 values
in the micromolar range. The two highly active compounds 6
and 11 were also examined for their eﬀects on tubulin
polymerization and as inhibitors of the binding of [3H]vinblas-
tine, [3H]dolastatin 10, and [3H]halichondrin B to tubulin
(Table 2). In these studies, they were found to be active as
tubulin inhibitors, although less active than HTI-286 (com-
pound 2). Their reduced activity in the tubulin assays is in
agreement with their reduced cytotoxicity as compared with 2
(compare data in Tables 1 and 2). We think it is most likely
that their interactions with tubulin are similar to those of
hemiasterlin (1) and HTI-286 (2). Compound 6 retains a high
structural similarity to the natural product hemiasterlin 1,
highlighting the possibility that further modifications of the
aromatic moiety in the first (A) amino acid segment will yield
interesting and active agents. With regard to compound 11,
closely related structurally to E7974 (4), its potent activity
suggests a marginal role of the piperidine ring stereogenic
centre configuration, opening the way to more reliable and
straightforward synthetic approaches. Lastly, the poor activity
found with the oxazole-based derivatives 7–9 discourages
further extensive modifications on the central (B) amino acid
segment. In particular, the consistent structural modification
brought by the presence of the oxazole ring caused a remark-
able conformational bending, presumably forcing the mole-
cule into a less favorable conformation with respect to
bioactive compounds.
To demonstrate the presumptive antimitotic activity of 6
and 11, based on their antitubulin activities, we analyzed their
eﬀects on cell cycle progression in HeLa cells. As shown in
Fig. 4, the two compounds caused a significant G2/M arrest in
a concentration-dependent manner. In particular, compound
11 was very active, inducing cell cycle arrest at 5 nM, similar to
Table 2 Inhibition of tubulin assembly and the binding of [3H]vinblastine, [3H]dolastatin 10 and [3H]halichondrin B
Inhibition of bindingb of
Inhibition of tubulin assembly
IC50 (μM) ± SDa
[3H]vinblastine [3H]dolastatin 10 [3H]halichondrin B
% inhibition ± SDa
5 µM 20 µM 5 µM 20 µM 5 µM 20 µM
inhibitor inhibitor inhibitor
HTI-286 (2) 0.94 ± 0.01 41 ± 10 62 ± 20 2 ± 1 22 ± 3 21 ± 4 62 ± 10
6 10 ± 0.6 3 ± 1 22 ± 7 2 ± 1 27 ± 4 1 ± 1 11 ± 4
11 15 ± 2 4 ± 2 23 ± 8 0 21 0 0
a SD = standard deviation. b Ligand binding studies were performed in 0.1 M 4-morpholinethanesulfonate (pH 6.9 in 1 M stock solution adjusted
with NaOH)–0.5 mM MgCl2 containing 10 µM tubulin (1.0 mg ml
−1), 10 µM radiolabeled ligand, and inhibitors as indicated. The reaction
volume was 0.3 mL and the incubation time was 15 min at RT (around 20 °C). Ligands were mixed prior to tubulin addition. Duplicate aliquots
of each reaction mixture were applied to syringe columns of Sephadex G-50 (superfine) swollen in 0.1 M Mes–0.5 mM MgCl2. At least two
experiments performed for each condition.
Fig. 4 Percentage of cells in each phase of the cell cycle in HeLa cells
treated with HTI-286 (2) (panel A), 6 (panel B) and 11 (panel C) at the
indicated concentrations for 24 h. Cells were ﬁxed and labeled with pro-
pidium iodide and analyzed by ﬂow cytometry as described in the
Experimental section.
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the activity of HTI-286 (2). Compound 6 was less active, indu-
cing a G2/M block only at 50 nM. The increase in the pro-
portion of cells in the G2/M phase was accompanied by a
sharp decrease in the proportion of cells in the other phases
of the cell cycle.
Conclusions
In summary, the preparation of new hemiasterlin derivatives
was achieved, in which either the A or the B fragment was
alternatively replaced. The procedures exploited multicompo-
nent approaches, applied in three complementary isonitrile-
based versions, and were highly valuable for the rapid and con-
vergent synthesis of a small family of analogues. Our multi-
component approach was not previously used in preparing
hemiasterlin analogues and allowed us to prepare compounds
with unconventional modifications, such as compounds 7–9.
Biological evaluation confirmed that we had prepared two cyto-
toxic molecules, for which tubulin assembly inhibition and
ligand binding studies were also performed, with the activity
for the two analogues obtained in these assays. The two ana-
logues also caused a G2/M arrest in HeLa cells. We plan to con-
tinue our target-oriented synthesis programs, using addition
strategies relying on MCRs. Our goal is to replace the multistep
generation of sterically hindered amide functions with more
reliable multicomponent assembly reactions.
Experimental section
General information
All commercial materials (Aldrich, Fluka) were used without
further purification. All solvents were of reagent grade or
HPLC grade. All reactions were carried out under a nitrogen
atmosphere. All reactions were monitored by thin layer
chromatography (TLC) on precoated silica gel 60 F254; spots
were visualized with UV light or by treatment with a 1%
aqueous KMnO4 solution. Products were purified by flash
chromatography (FC) on silica gel 60 (230–400 mesh). 1H NMR
spectra and 13C NMR spectra were recorded on 300 and
400 MHz spectrometers. Chemical shifts are reported in parts
per million relative to the residual solvent. 13C NMR spectra
have been recorded using the APT pulse sequence. Multiplici-
ties in 1H NMR are reported as follows: s = singlet, d =
doublet, t = triplet, m = multiplet, br s = broad singlet. High-
resolution MS spectra were recorded with an FT-ICR (Fourier
Transform Ion Cyclotron Resonance) instrument, equipped
with an ESI source.
General procedure for preparation of aldehydes 13–16.
A solution of [Pd(η3-allyl)Cl]2 (0.03 mmol) and Q-phos
(0.06 mmol) in dry THF (10 mL) was prepared and stirred for
5 min at room temperature. Cs2CO3 (12 mmol), the required
Br-benzene or Br-indole (6 mmol) and isobutyraldehyde
(7 mmol) were then added. The reaction mixture was stirred
for 18 h at 80 °C and then was diluted with EtOAc (20 mL) and
filtered through a pad of Celite®. The filtrate was concentrated
in vacuo, and the crude product was purified by FC.
2-(4-Methoxyphenyl)-2-methylpropanal 13.13 FC (7 : 3,
n-hexane/DCM); 75% yield; yellow oil; Rf 0.27 (7 : 3, n-hexane/
dichloromethane); 1H NMR (300 MHz, CDCl3) and
13C NMR
(75 MHz, CDCl3) in accordance with the literature. HRMS (ESI)
calcd for C11H15O2
+ [MH]+ 179.1067, found 179.1075.
2-Methyl-2-(1-methyl-1H-indol-5-yl)propanal 14. FC (7 : 3,
n-hexane/DCM); 57% yield; oil; Rf 0.2 (1.5 : 1, n-hexane/
dichloromethane); 1H NMR (300 MHz, CDCl3) δ 9.50 (s, 1H),
7.56 (s, 1H), 7.26 (d, J = 8.5 Hz, 1H), 7.18–7.03 (m, 2H), 6.47 (d,
J = 2.9 Hz, 1H), 3.75 (s, 3H), 1.53 (s, 6H); 13C NMR (75 MHz,
CDCl3) δ 202.7, 135.8, 131.8, 129.5, 128.8, 120.6, 118.8, 109.6,
101.1, 51.0, 33.6, 23.2 (2C); HRMS (ESI) calcd for C13H15NNaO
+
[MNa]+ 224.1046, found 224.1054.
2-Methyl-2-phenylpropanal 15.13 FC (7 : 3, n-hexane/DCM);
50% yield; yellow oil; Rf 0.2 (4 : 1, n-hexane/dichloromethane);
1H NMR (300 MHz, CDCl3) and
13C NMR (75 MHz, CDCl3) in
accordance with the literature. HRMS (ESI) calcd for
C10H12NaO
+ [MNa]+ 171.0780, found 171.0792.
2-Methyl-2-(1-methyl-1H-indol-3-yl)propanal 16. FC (7 : 3,
n-hexane/DCM); 46%; oil; Rf 0.2 (1.5 : 1, n-hexane/dichloro-
methane); 1H NMR (300 MHz, CDCl3) δ 9.48 (s, br, 1H), 7.55
(d, br, J = 7.7 Hz, 1H), 7.32 (d, J = 7.8 Hz, 1H), 7.24 (t, br, J =
7.8 Hz, 1H), 7.10 (t, J = 7.7 Hz, 1H), 6.96 (s, br, 1H), 3.79 (s, br,
3H), 1.56 (m, br, 6H); 13C NMR (75 MHz, CDCl3) δ 202.3,
137.7, 130.9, 126.2, 121.9, 120.3, 119.4, 115.1, 109.6, 46.5, 32.8,
22.0 (2C); HRMS (ESI) calcd for C13H16NO
+ [MH]+ 202.1226,
found 202.1234.
(S)-Methyl 2-isocyano-3-methylbutanoate 17.16 Prepared
according to the literature.16 Spectroscopic and optical rotatory
power data as in the literature.25
(S)-Methyl 2-((S)-3-(4-methoxyphenyl)-3-methyl-2-(2,2,2-tri-
fluoro-N-methylacetamido)butanamido)-3-methylbutanoate
18a and (S)-methyl 2-((R)-3-(4-methoxyphenyl)-3-methyl-2-
(2,2,2-trifluoro-N-methylacetamido)butanamido)-3-methyl-
butanoate 18b. Aldehyde 13 (250 mg, 1.40 mmol) and
methylamine (1 M in MeOH, 1.54 mL, 1.54 mmol) were dis-
solved in dry MeOH (2.8 mL), anhydrous MgSO4 (1.26 g) was
then added, and the mixture was stirred for 2 h at 25 °C. Tri-
fluoroacetic acid (128 mL, 1.68 mmol) and α-isocyanoacetate
17 (238 mg, 1.68 mmol) were added with a time gap of
20 minutes between the two additions. With all the reactants
added, the mixture was stirred for 48 h. The reaction mixture
was then concentrated in vacuo to give a residue that was puri-
fied by FC (4 : 1, n-hexane/ethyl acetate) to give 18a (200 mg,
32%) and 18b (194 mg, 31%). 18a: white amorphous solid;
Rf (9 : 1 n-hexane/ethyl acetate) 0.17; [α]
21
D = +46.4 (c = 0.1,
CHCl3);
1H NMR (300 MHz, CDCl3) δ 7.42 (d, J = 8.7 Hz, 2H),
6.89 (d, J = 8.7 Hz, 2H), 5.68 (d, br, J = 7.8 Hz, 1H), 5.47 (s, 1H),
4.30 (dd, J = 8.7, 4.9 Hz, 1H), 3.78 (s, 3 H), 3.69 (s, 3H), 3.26 (s,
br, 3H), 1.97 (m, 1H), 1.61 (s, 3H), 1.41 (s, 3H), 0.74 (d, J =
6.8 Hz, 3H), 0.64 (d, J = 6.8 Hz, 3H); 13C NMR (75 MHz, CDCl3)
δ 171.6, 168.0, 158.9 (q, J = 34.9 Hz), 158.5, 137.8, 127.5 (2C),
116.5 (q, J = 287.7 Hz), 113.8 (2C), 65.0, 57.1, 55.2, 42.0, 41.7,
33.7, 30.5, 27.5, 25.5, 18.8, 17.4; HRMS (ESI) calcd for
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C21H29F3N2O5
+ [MNa]+ 469.1921, found 469.1919. 18b: white
amorphous solid; Rf (9 : 1 n-hexane/ethyl acetate) 0.18; [α]
21
D =
+26.3 (c = 0.1, CHCl3);
1H NMR (300 MHz, CDCl3) δ 7.39 (d, J =
8.7 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 5.82 (d, J = 8.1 Hz, 1H),
5.45 (s, 1H), 4.30 (dd, J = 8.4, 4.7 Hz, 1H), 3.77 (s, 3H), 3.65 (s,
3H), 3.22 (s, 3H) 1.96 (m, 1H), 1.61 (s, 3H), 1.41 (s, 3H), 0.70
(d, J = 6.8 Hz, 3H), 0.69 (d, J = 6.8 Hz, 3H); 13C NMR (75 MHz,
CDCl3) δ 171.5, 167.7, 159.4 (q, J = 34.9 Hz), 158.4, 137.5, 127.7
(2C), 116.4 (q, J = 287.7 Hz), 113.8 (2C), 64.8, 57.2, 55.3, 52.2,
41.8, 33.5, 30.7, 27.2, 25.5, 18.7, 17.7; HRMS (ESI) calcd for
C21H29F3N2O5
+ [MNa]+ 469.1921, found 469.1931.
(S)-Methyl 3-methyl-2-((S)-3-methyl-3-(1-methyl-1H-indol-
5-yl)-2-(2,2,2-trifluoro-N-methylacetamido)butanamido)butano-
ate 19a and (S)-methyl 3-methyl-2-((R)-3-methyl-3-(1-methyl-
1H-indol-5-yl)-2-(2,2,2-trifluoro-N-methylacetamido)butan-
amido)butanoate 19b. Aldehyde 14 (250 mg, 1.24 mmol) and
methylamine (1 M in MeOH, 1.37 mL, 1.37 mmol) were dis-
solved in dry MeOH (2.5 mL), anhydrous MgSO4 (1.15 g) was
then added, and the mixture was stirred for 2 h at 25 °C. Tri-
fluoroacetic acid (115 mL, 1.49 mmol) and α-isocyanoacetate
17 (210 mg, 1.49 mmol) were added with a time gap of 20 min
between the two additions. With all the reactants added, the
mixture was stirred for 48 h. The reaction mixture was then
concentrated in vacuo to give a residue that was purified by FC
(4 : 1, n-hexane/ethyl acetate) to give 19a (215 mg, 37%) and
19b (221 mg, 38%). 19a: white amorphous solid; Rf (5.7 : 1
n-hexane/ethyl acetate) 0.17; [α]21D = +53.0 (c = 0.1, CHCl3);
1H NMR (300 MHz, CDCl3) δ 7.77 (s, br, 1H), 7.43 (dd, J =
8.8 and 2.0 Hz, 1H), 7.33 (d, br, J = 8.8 Hz, 1H), 7.04 (d, J =
2.9 Hz, 1H), 6.46 (d, br, J = 2.9 Hz, 1H), 5.75 (s, 1H), 5.65 (d,
br, J = 7.8 Hz, 1 H), 4.22 (dd, J = 7.8 and 4.9 Hz, 1H), 3.77 (s,
3H), 3.60 (s, 3H), 3.31 (s, br, 3H), 1.83 (m, 1H), 1.72 (s, 3H),
1.45 (s, 3H), 0.59 (d, J = 6.8 Hz, 3H), 0.37 (d, J = 7.0 Hz, 3H);
13C NMR (75 MHz, CDCl3) δ 171.6, 168.4, 158.4 (q, J = 34.9 Hz),
136.9, 135.5, 129.5, 128.7, 120.0, 119.6, 116.5 (q, J = 287.7 Hz),
109.8, 101.0, 65.6, 57.2, 51.8, 42.2, 34.1, 32.8, 30.2, 28.3, 25.2,
18.7, 17.0; HRMS (ESI) calcd for C23H30F3N3NaO4
+ [MNa]+
492.2081, found 492.2071. 19b: white amorphous solid; Rf
(5.7 : 1 n-hexane/ethyl acetate) 0.18; [α]D
21 = +30.2 (c = 0.1,
CHCl3);
1H NMR (300 MHz, CDCl3) δ 7.69 (s, br, 1H), 7.40 (dd,
J = 8.7 and 2.0 Hz, 1H), 7.31 (d, br, J = 8.7 Hz, 1H), 7.03 (d, J =
2.9 Hz, 1H), 6.43 (d, J = 2.9 Hz, 1H), 5.67 (d, br, J = 7.8 Hz, 1H),
5.58 (s, 1H), 4.25 (dd, J = 7.8 and 4.9 Hz, 1H), 3.77 (s, 3H), 3.56
(s, 3H), 3.31 (s, 3H), 1.78 (m, 1H), 1.71 (s, 3H), 1.48 (s, 3H),
0.53 (d, J = 6.8 Hz, 3H), 0.51 (d, J = 6.8 Hz, 3H); 13C NMR
(75 MHz, CDCl3) δ 171.3, 167.9, 158.4 (q, J = 34.9 Hz), 136.5,
135.6, 129.4, 128.6, 120.1, 118.4, 116.5 (q, J = 287.7 Hz), 109.4,
101.2, 65.2, 57.2, 51.9, 42.3, 33.6, 32.8, 30.6, 27.9, 25.5, 18.3,
17.5; HRMS (ESI) calcd for C23H30F3N3NaO4
+ [MNa]+ 492.2081,
found 492.2066.
(S,E)-Ethyl 2,5-dimethyl-4-(methylamino)hex-2-enoate 20.20 Pre-
pared according to the literature. Spectroscopic and optical
rotatory power data as in the literature.
(S,E)-Ethyl 4-((S)-2-((S)-3-(4-methoxyphenyl)-3-methyl-2-
(2,2,2-trifluoro-N-methylacetamido)butanamido)-N,3-dimethyl-
butanamido)-2,5-dimethylhex-2-enoate 21. LiOH (24 mg,
1.0 mmol) was added to a suspension of methyl ester 18a
(88 mg, 0.2 mmol) in 50% aqueous methanol (v/v, 8 mL). The
resulting mixture was stirred for 18 h at 25 °C and then diluted
with water (10 mL) and extracted with diethyl ether (2 × 7 mL).
The aqueous layer was acidified to pH 2–3 with a 5% aqueous
solution of H3PO4 and extracted with EtOAc (3 × 5 mL). The
combined organic layers were dried over Na2SO4 and concen-
trated in vacuo to aﬀord the crude acid intermediate, which
was used in the condensation step without purification. HBTU
(60 mg, 0.15 mmol) was added to a solution of the crude acid
(60 mg, 0.14 mmol) in dry dichloromethane (3 mL). After
10 min, amine 20 (30 mg, 0.15 mmol) and DIPEA (30 mL,
0.17 mmol) in dry dichloromethane (3 mL) were added. The
resulting reaction mixture was stirred for 24 h at 25 °C and
then washed with a saturated aqueous solution of NaHCO3
(two times), water and finally with a 5% aqueous solution of
H3PO4. The resulting organic layer was dried over Na2SO4 and
concentrated in vacuo. The crude residue was purified by FC
(4 : 1, n-hexane/ethyl acetate) to give 21 (48 mg, 58%). Pale
yellow oil; Rf (4 : 1, n-hexane/ethyl acetate) 0.25; [α]
23
D = −57.4
(c = 0.12, CHCl3);
1H NMR (400 MHz, CDCl3) δ 7.39 (d, J =
8.8 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 6.61 (dq, br, J = 9.2 and
1.5 Hz, 1H), 6.09 (d, br, J = 8.6 Hz, 1H), 5.44 (s, 1H), 5.01 (dd,
J = 10.5 and 9.2 Hz, 1H), 4.52 (dd, J = 8.6 and 6.8 Hz, 1H), 4.18
(q, J = 7.0 Hz, 2H), 3.77 (s, 3H), 3.15 (q, br, J = 1.7 Hz, 3H), 2.88
(s, 3H), 1.93–1.75 (m, br, 2H), 1.85 (d, J = 1.5 Hz, 3H), 1.54 (s,
3H), 1.40 (s, 3H), 1.28 (t, J = 7.0 Hz, 3 H), 0.88 (d, J = 6.6 Hz,
3H), 0.81 (d, J = 6.6 Hz, 3H), 0.78 (d, J = 6.8 Hz, 3H), 0.65 (d, J =
6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 172.3, 167.9, 167.7,
158.4 (q, J = 34.9 Hz), 158.0, 138.2, 137.6, 132.9, 127.5 (2C),
116.6 (q, J = 287.7 Hz), 114.0 (2C), 65.0, 60.9, 56.4, 55.3, 54.0,
41.6, 33.5, 30.8, 30.3, 30.0, 27.3, 26.4, 19.4 (2C), 18.8, 17.3,
14.2, 13.7; HRMS (ESI) calcd for C31H46F3N3NaO6
+ [MNa]+
636.3231, found 636.32423.
(S,E)-4-((S)-2-((S)-3-(4-Methoxyphenyl)-3-methyl-2-(methyl-
amino)butanamido)-N,3-dimethyl-butanamido)-2,5-dimethyl-
hex-2-enoic acid 5. LiOH (16 mg, 0.64 mmol) was added to a
suspension of ester 21 (50 mg, 0.08 mmol) in 50% aqueous
methanol (v/v, 3 mL). The resulting mixture was stirred for
18 h at 60 °C, then diluted with water (10 mL) and extracted
with diethyl ether (2 × 10 mL). The aqueous layer was acidified
to pH 2–3 with a 5% aqueous solution of H3PO4 and extracted
with EtOAc (3 × 10 mL). The combined organic layers were
dried over Na2SO4 and concentrated in vacuo to aﬀord pure
5 (30 mg, 76%). Foam; [α]23D = −47.1 (c = 0.58, CHCl3); 1H NMR
(400 MHz, CDCl3) δ 7.29 (d, J = 8.7 Hz, 2H), 7.28 (m, br, 1H),
6.89 (d, J = 8.7 Hz, 2H), 6.94–6.66 (m, br, 2H), 6.79 (dq, br, J =
9.9 and 1.5 Hz, 1H), 5.15 (dd, J = 9.9 and 5.3 Hz, 1H), 4.48 (d,
J = 10.9 Hz, 1H), 3.98 (s, 1H), 3.82 (s, 3H), 3.24 (dhept, J = 10.9
and 6.7 Hz, 1H), 2.93 (s, 3H), 2.33 (s, 3H), 1.96 (s, br, 3H), 1.89
(m, 1H), 1.60 (s, 3H), 1.35 (s, 3H), 0.92–0.87 (m, 9H), 0.86 (d,
J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 172.3, 171.3,
169.6, 158.4, 140.5, 137.8, 131.8, 127.4 (2C), 113.9 (2C), 70.6,
58.4, 56.7, 55.3, 41.3, 31.8, 30.3, 29.8, 27.7, 27.0, 20.9, 19.7,
19.6, 19.5, 19.4, 13.5; HRMS (ESI) calcd for C27H44N3O5
+ [MH]+
490.3275, found 490.3270.
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(S,E)-Ethyl 4-((S)-N,3-dimethyl-2-((S)-3-methyl-3-(1-methyl-
1H-indol-5-yl)-2-(2,2,2-trifluoro-N-methyl acetamido)butan-
amido)butanamido)-2,5-dimethylhex-2-enoate 22. LiOH
(20 mg, 0.83 mmol) was added to a suspension of methyl ester
19a (78 mg, 0.17 mmol) in 50% aqueous methanol (v/v, 7 mL).
The resulting mixture was stirred for 18 h at 25 °C, then
diluted with water (10 mL) and extracted with diethyl ether
(2 × 5 mL). The aqueous layer was acidified to pH 2–3 with a
5% aqueous solution of H3PO4 and extracted with EtOAc (3 ×
5 mL). The combined organic layers were dried over Na2SO4
and concentrated in vacuo to aﬀord the crude acid intermedi-
ate, which was used in the condensation step without purifi-
cation. HBTU (76 mg, 0.20 mmol) was added to a solution of
the crude acid (77 mg, 0.17 mmol) in dry dichloromethane
(3.5 mL). After 10 min, amine 20 (40 mg, 0.20 mmol) and
DIPEA (38 mL, 0.22 mmol) in dry dichloromethane (3.5 mL)
were added. The resulting reaction mixture was stirred for 24 h
at 25 °C, and then washed with a saturated aqueous solution
of NaHCO3 (two times), water and finally with a 5% aqueous
solution of H3PO4. The resulting organic layer was dried over
Na2SO4 and concentrated in vacuo. The crude residue was puri-
fied by FC (3 : 1, n-hexane/ethyl acetate) to give 22 (58 mg,
52%). Pale yellow foam; Rf (3 : 1, n-hexane/ethyl acetate) 0.28;
[α]21D = −78.1 (c = 0.1, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.80
(s, br, 1H), 7.41 (d, br, J = 8.7 Hz, 1H), 7.34 (d, J = 8.7 Hz, 1H),
7.06 (d, J = 2.9 Hz, 1H), 6.64 (d, br, J = 8.9 Hz, 1H), 6.49 (d, J =
2.9 Hz, 1H), 6.14 (d, J = 8.2 Hz, 1H), 5.71 (s, 1 H), 5.04 (t, J =
9.9 Hz, 1H), 4.46 (t, J = 7.6 Hz, 1H), 4.21 (q, J = 6.7 Hz, 2H),
3.80 (s, 3H), 3.21 (s, 3H), 2.89 (s, 3H), 1.88 (s, 3H), 1.93–1.78
(m, 1H), 1.78–1.64 (m, 1H), 1.69 (s, 3H), 1.50 (s, 3H), 1.82 (t, J =
6.7 Hz, 3H), 0.91 (d, J = 6.5 Hz, 3H), 0.80 (d, J = 6.5 Hz, 3H),
0.72 (d, J = 6.7 Hz, 3H), 0.47 (d, J = 6.7 Hz, 3H); 13C NMR
(100 MHz, CDCl3) δ 172.1, 168.9, 168.4, 158.9 (q, J = 35.3 Hz),
139.1, 137.4, 136.2, 133.5, 130.1, 129.3, 120.80, 119.1, 117.3 (q,
J = 288.2 Hz), 110.3, 102.0, 66.3, 61.5, 57.0, 54.9, 42.7, 34.5,
33.5, 31.3, 30.9, 30.6, 30.6, 28.7, 27.0, 20.0, 19.9, 19.4, 17.9,
14.9; HRMS (ESI) calcd for C33H47F3N4NaO5
+ [MNa]+ 659.3391,
found 659.3384.
(S,E)-4-((S)-N,3-Dimethyl-2-((S)-3-methyl-3-(1-methyl-1H-indol-
5-yl)-2-(methylamino)butanamido)butanamido)-2,5-dimethyl-
hex-2-enoic acid 6. LiOH (10 mg, 0.4 mmol) was added to a
suspension of ester 22 (35 mg, 0.05 mmol) in 50% aqueous
methanol (v/v, 2 mL). The resulting mixture was stirred for
18 h at 60 °C, then diluted with water (10 mL) and extracted
with diethyl ether (2 × 5 mL). The aqueous layer was acidified
to pH 2–3 with a 5% aqueous solution of H3PO4 and extracted
with EtOAc (3 × 8 mL). The combined organic layers were
dried over Na2SO4 and concentrated in vacuo to aﬀord almost
pure 6 (17 mg, 65%). Pale yellow foam; [α]20D = −56.5 (c = 0.1,
CHCl3);
1H NMR (400 MHz, CD3OD) δ 7.67 (s, 1H), 7.38 (d, J =
8.7 Hz, 1H), 7.30 (d, br, J = 8.7 Hz, 1H), 7.17 (d, J = 3.2 Hz, 1H),
6.75 (d, br, J = 9.3 Hz, 1H), 6.44 (d, J = 3.2 Hz, 1H), 4.98 (dd, J =
10.2 and 9.3 Hz, 1H), 4.48 (d, J = 10.5 Hz, 1H), 4.34 (s, 1H),
3.81 (s, 3H), 3.05 (m, 1H), 3.03 (s, 3H), 2.25 (s, 3H), 2.01 (m,
1H), 1.90 (s, 3H), 1.66 (s, 3H), 1.49 (s, 3H), 0.91 (d, br, J =
6.7 Hz, 6H), 0.85 (d, br, J = 6.5 Hz, 3H), 0.80 (d, br, J = 6.7 Hz,
3H); 13C NMR (100 MHz, CD3OD) δ 172.4, 168.9, 168.0, 138.6,
136.8, 136.3, 134.3, 129.8, 128.4, 120.3, 118.5, 109.4, 101.9,
70.7, 58.7, 57.8, 42.0, 32.2, 31.1, 30.2, 29.7, 28.0, 27.7, 27.5,
19.1 (2C), 18.9, 18.8, 13.2; HRMS (ESI) calcd for C29H45N4O4
+
[MH]+ 513.3435, found 513.3422.
(4S,E)-Ethyl 4-((4-isopropyl-2-(2-methyl-1-(methylamino)-2-
phenylpropyl)oxazol-5-yl)(methyl)amino)-2,5-dimethylhex-2-
enoate 7. A mixture of aldehyde 15 (50 mg, 0.34 mmol),
methylamine (2 M solution in MeOH, 0.25 mL, 0.50 mmol)
and MgSO4 (20 mg) in MeOH (0.6 mL) was stirred for 2.5 h.
Then isocyanide 23 (95 mg, 0.31 mmol) was added. After 48 h
the reaction mixture was filtered through a Celite® pad and
concentrated in vacuo. The residue was purified by FC (1.5 : 1,
n-hexane/ethyl acetate) to give 7 (73 mg, 51%) as a 1.5 : 1 in-
separable mixture of two diastereoisomers. White foam;
Rf 0.38 (1 : 1.5, n-hexane/ethyl acetate);
1H NMR (400 MHz,
CDCl3) δ 7.56–7.18 (m, 5H), 6.67 (d, br, J = 9.8 Hz, 1H), 4.21 (q,
J = 7.1 Hz, 2H), 3.76 (s, 0.6H), 3.73 (s, 0.4 H), 3.43 (m, 1H), 2.86
(m, 1H), 2.57 (s, 3H), 2.21 (s, 3H), 1.81 (s, 3H), 1.76 (m, 1H),
1.39 (s, 6H), 1.30 (t, J = 7.1 Hz, 3H), 1.22 (m, 6H), 0.91 (m, 3H),
0.84 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 168.3, 159.6, 149.9,
146.0, 140.1, 139.9, 135.0, 131.9, 129.3 (2C), 127.0 (2C), 126.5,
69.7, 67.3, 61.3, 42.6, 40.2, 35.8, 30.9, 26.5, 24.8, 24.3, 21.8
(2C), 19.9 (2C), 14.9; HRMS (ESI) calcd for C28H43N3NaO3
+
[MNa]+ 492.3197, found 492.3209.
(4S,E)-Ethyl 4-((4-isopropyl-2-(2-(4-methoxyphenyl)-2-methyl-
1-(methylamino)propyl)oxazol-5-yl)(methyl)amino)-2,5-dimethyl-
hex-2-enoate 8. A mixture of aldehyde 13 (34 mg, 0.19 mmol),
methylamine (2 M solution in MeOH, 0.15 mL, 0.30 mmol)
and MgSO4 (15 mg) in MeOH (0.6 mL) was stirred for 2.5 h.
Then isocyanide 23 (60 mg, 0.19 mmol) was added. After 48 h
the reaction mixture was filtered through a Celite® pad and
concentrated in vacuo. The residue was purified by FC (7 : 3,
n-hexane/ethyl acetate) to give 8 (66 mg, 68%) as a 1.5 : 1 in-
separable mixture of two diastereoisomers. White foam; Rf 0.4
(1 : 1.5, n-hexane/ethyl acetate); 1H NMR (400 MHz, CDCl3)
δ 7.24 (d, J = 8.8 Hz, 2H), 6.83 (d, J = 8.8 Hz, 2H), 6.67 (m, 1H),
4.21 (q, J = 7.1 Hz, 2H), 3.79 (s, 3H), 3.72 (s, 0.6H), 3.69 (s,
0.4H), 3.43 (m, 1H), 2.88 (m, 1H), 2.61 (s, 3H), 2.21 (s, 3H),
1.81 (s, br, 3H), 1.76 (m, 1H), 1.43 (s, 6H), 1.30 (t, J = 7.1 Hz,
3H), 1.19 (m, 6H), 0.97 (m, 3H), 0.85 (m, 3H); 13C NMR
(100 MHz, CDCl3) δ 167.6, 159.2, 157.9, 149.6, 139.4, 138.2,
134.3, 130.1, 127.5 (2C), 113.4 (2C), 69.2, 66.7, 60.6, 55.2, 41.4,
39.6, 35.1, 30.3, 26.5, 24.9, 24.3 (2C), 21.8 (2C), 19.9 (2C), 13.1;
HRMS (ESI) calcd for C29H45N3NaO4
+ [MNa]+ 522.3302, found
522.3317.
(4S,E)-Ethyl 4-((4-isopropyl-2-(2-methyl-2-(1-methyl-1H-indol-
3-yl)-1-(methylamino)propyl)oxazol-5-yl)(methyl)amino)-2,5-di-
methylhex-2-enoate 9. A mixture of aldehyde 16 (40 mg,
0.20 mmol), methylamine (2 M solution in MeOH, 0.15 mL,
0.30 mmol) and MgSO4 (15 mg) in MeOH (0.6 mL) was stirred
for 2.5 h. Then isocyanide 23 (65 mg, 0.21 mmol) was added.
After 48 h the reaction mixture was filtered through a Celite®
pad and concentrated in vacuo. The residue was purified by FC
(1.5 : 1, n-hexane/ethyl acetate) to give 9 (66 mg, 64%) as a 1 : 1
inseparable mixture of two diastereoisomers. Thick oil; Rf 0.38
Paper Organic & Biomolecular Chemistry
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(1 : 1.5, n-hexane/ethyl acetate); 1H NMR (400 MHz, CDCl3)
δ 7.85 (d, J = 8.2 Hz, 0.5H), 7.83 (d, J = 8.2 Hz, 0.5H), 7.30 (d,
J = 8.1 Hz, 1H), 7.22 (t, br, J = 8.1 Hz, 1H), 7.09 (t, br, J =
7.9 Hz, 1H), 6.88 (s, 1H), 6.72 (d, br, J = 9.8 Hz, 0.5H), 6.69 (d,
br, J = 9.8 Hz, 0.5H), 4.21 (q, J = 7.1 Hz, 2H), 4.13 (s, 0.5H),
4.11 (s, 0.5H), 3.75 (s, 3H), 3.47 (m, 1H), 2.86 (m, 1H), 2.59 (s,
1.5H), 2.57 (s, 1.5H), 2.14 (s, 3H), 1.92–1.81 (m, 4H), 1.50 (s,
3H), 1.41 (s, 3H), 1.30–1.21 (m, 10H), 0.95 (m, 3H), 0.84 (m,
3H); 13C NMR (100 MHz, CDCl3) δ 168.4, 160.2, 150.0, 140.2,
140.0, 135.1, 134.9, 127.6 (2C), 126.7, 122.7, 121.9, 119.3,
110.8, 68.3, 67.3, 61.3, 40.1, 40.0, 36.0, 33.3, 31.0, 27.7, 27.5,
25.7, 24.5, 22.5, 21.8, 20.1, 20.5, 18.3; HRMS (ESI) calcd for
C31H46N4NaO3
+ [MNa]+ 545.3462, found 545.3455.
(S,E)-Ethyl 4-((S)-2-amino-N,3-dimethylbutanamido)-2,5-di-
methylhex-2-enoate 24.22 Prepared according to the literature.
Spectroscopic and optical rotatory power data were in accord
with the literature.
(S,E)-Ethyl 4-((S)-2-formamido-N,3-dimethylbutanamido)-
2,5-dimethylhex-2-enoate 25. Acetic formic anhydride (pre-
pared by stirring 1 equiv. of acetic anhydride and 1.1 equiv. of
formic acid for 2 h at 55 °C, 0.85 mL, 13.5 mmol) was added
dropwise at 0 °C to a stirred solution of amine 24 (0.84 g,
2.8 mmol) in dichloromethane (10 mL), and the mixture was
stirred for 18 h at room temperature. After elimination of all
volatiles under reduced pressure, compound 25 was obtained
(0.91 g, quantitative yield). Oil; Rf 0.4 (ethyl acetate); [α]
21
D =
−103.5 (c 1.3, CHCl3); 1H NMR (300 MHz, CDCl3) δ 8.21 (s,
1H), 6.62 (d, J = 9.2 Hz, 1H), 6.50 (d, br, J = 8.8 Hz, 1H), 5.09
(dd, J = 10.0 Hz and 9.4 Hz, 1H), 4.94 (dd, J = 7.0 Hz and
8.8 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 2.97 (s, 3H), 2.08–1.77 (m,
5H), 1.30 (t, J = 7.1 Hz, 3H), 0.85 (m, 12H); 13C NMR (75 MHz,
CDCl3) δ 172.1, 167.7, 161.3, 137.8, 133.1, 60.9, 56.7, 52.6, 32.0,
30.6, 29.9, 19.3 (2C), 18.7, 17.5, 14.2, 13.6; HRMS (ESI) calcd
for C17H31N2O4
+ [MH]+ 327.2278, found 327.2290.
(S,E)-Ethyl 4-((S)-2-isocyano-N,3-dimethylbutanamido)-2,5-
dimethylhex-2-enoate 23. Formamide 25 (0.90 g, 2.76 mmol)
was dissolved in dry THF (40 mL), and N-methylmorpholine
(1.13 mL, 10.2 mmol) was added. The resulting solution was
cooled to −30 °C, and diphosgene (0.2 mL, 1.66 mmol) in THF
(1.5 mL) was added dropwise over a period of 15 min, while
the temperature was maintained at −30 °C. After the addition
of diphosgene was completed, the solution was allowed to
warm to 0 °C. Then an ice-cold saturated aqueous sodium
bicarbonate solution (10 mL) was added, and the reaction
mixture was stirred vigorously for 10 min. The product was
extracted with EtOAc (25 mL), and the EtOAc phase was
washed sequentially with a saturated aqueous sodium bicarb-
onate solution and brine. The organic layer was dried over
Na2SO4 and evaporated in vacuo. The product was purified by
FC (4 : 1, n-hexane/ethyl acetate) to give 23 (0.67 g, 80%).
Yellow oil; Rf 0.26 (4 : 1, n-hexane/ethyl acetate); [α]
19
D = −91.8
(c 1.1, CH3OH);
1H NMR (300 MHz, CD3OD) δ 6.70 (d, J = 9.2
Hz, 1H), 4.97 (dd, J = 10.0 and 9.2 Hz, 1H), 4.70 (d, J = 5.9 Hz,
1H), 4.20 (q, J = 7.1 Hz, 2H), 2.94 (s, 3H), 2.30 (m, 1H), 1.90 (m,
1H), 1.86 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H), 1.09 (m, 6H), 0.85 (m,
6H); 13C NMR (75 MHz, CD3OD) δ 169.2, 168.1, 159.4, 139.2,
134.5, 62.4, 62.0, 59.3, 32.5, 31.8, 31.4, 19.4–19.3 (3C), 18.5,
14.5, 13.8; HRMS (ESI) calcd for C17H28N2NaO3
+ [MNa]+
331.1992, found 331.2008.
α-Tripiperideine 26.17 Prepared according to the literature.
Spectroscopic data were in accord with the literature.
(2S)-Methyl 3-methyl-2-(1-(pent-4-enoyl)piperidine-2-carbox-
amido)butanoate 27. A solution of pent-4-enoic acid (579 μL,
5.67 mmol) and α-tripiperideine 26 (466 mg, 1.87 mmol) in
dry MeOH (12 mL) was stirred for 10 min. Isocyanoacetate 17
(880 mg, 6.24 mmol) was then added, and the mixture was
stirred at 25 °C for 72 h. The solvent was removed in vacuo,
and the crude mixture was taken in EtOAc (15 mL) and washed
with a saturated aqueous solution of NaHCO3 (3 × 10 mL). The
organic layers were dried over Na2SO4, and the solvent was
concentrated in vacuo. The crude product was purified by FC
(7 : 3 to 1.5 : 1 gradient, n-hexane/ethyl acetate) to give 27
(843 mg, 46%) as an inseparable 1 : 1 mixture of diastereo-
isomers. Yellow oil; Rf 0.29 (7 : 3, n-hexane/ethyl acetate);
1H
NMR (400 MHz, CDCl3) δ 6.69–6.59 (m, 1H), 5.96–5.83 (m, 1H),
5.32 (d, br, J = 5.4 Hz, 0.5H), 5.26 (d, br, J = 5.4 Hz, 0.5H), 5.10
(d, m, J = 17.1 Hz, 1H), 5.03 (d, br, J = 10.0 Hz, 1H), 4.50 (dd,
J = 5.4 and 3.9 Hz, 0.5H), 4.48 (dd, J = 5.0 and 3.2 Hz, 0.5H),
3.85–3.75 (m, 1H), 3.74 (1.5 H, s), 3.73 (1.5 H, s), 3.17 (dt, J =
13.2 and 3.2 Hz, 0.5H), 3.14 (dt, J = 13.2 and 3.2 Hz, 0.5H),
2.58–2.50 (m, 2H), 2.50–2.41 (m, 2H), 2.33–2.14 (m, 2H),
1.78–1.65 (m, 3H), 1.60–1.42 (m, 2H), 0.96 (d, J = 6.8 Hz, 1.5H),
0.93 (d, J = 6.8 Hz, 1.5H), 0.88 (d, J = 6.9 Hz, 3H); 13C NMR
(100 MHz, CDCl3) δ 173.1 and 172.8 (1C), 172.5 and 172.
0 (1C), 171.3, 137.2, 115.4, 57.3, 52.1 and 52.0 (1C), 51.9 and
51.8 (1C), 43.8 and 43.7 (1C), 32.8 and 32.7 (1C), 31.0 and 30.7
(1C), 29.2, 25.5, 25.3 and 25.0 (1C), 20.4 and 20.3 (1C), 19.1,
17.7 and 17.6 (1C); HRMS (ESI) calcd for C17H28N2NaO4
+
[MNa]+ 347.1941, found 347.1958.
(2S)-Methyl 3-methyl-2-(piperidine-2-carboxamido)butano-
ate 28. Iodine (117 mg, 0.46 mmol) was added to a solution of
compound 27 (100 mg, 0.31 mmol) in THF/H2O (6 mL, 31 v/v).
After stirring for 30 min, aqueous Na2S2O3 (20 mL, 1 M) was
added, and the suspension thus obtained was stirred for
30 min. The mixture was then poured into an aqueous solution
of Na2S2O3/brine (20 mL 1 : 1 v/v) and extracted with EtOAc
(3 × 20 mL). The combined organic layers were dried over
Na2SO4 and concentrated in vacuo to give a yellow residue that
was taken in diethyl ether (10 mL) and washed with a 1 M
aqueous solution of HCl (3 mL × 2). The aqueous phase was
basified to pH 9 with a saturated aqueous solution of NaHCO3
and extracted with dichloromethane (3 × 10 mL). The com-
bined organic phases were dried over Na2SO4 and concentrated
in vacuo to give compound 28 (64 mg, 85%) as an inseparable
1 : 1 mixture of diastereoisomers. Yellow oil; 1H NMR
(300 MHz, CDCl3) δ 7.40–7.30 (m, 1H), 4.51 (t, br, J = 5.8 Hz,
0.5H), 4.49 (t, br, J = 5.4 Hz, 0.5H), 3.70 (s, 3H), 3.40–3.28 (m,
1H), 3.14–3.00 (m, 1H), 2.79–2.65 (m, 1H), 2.65–2.48 (m, 1H),
2.17 (oct, J = 5.9 Hz, 1H), 2.13–1.88 (m, 1H), 1.85–1.69 (m, 1H),
1.63–1.37 (m, 4H), 0.95–0.87 (m, 6H); 13C NMR (75 MHz,
CDCl3) δ 173.7 and 173.5 (1C), 172.5 and 172.4 (1C), 60.1 and
60.0 (1C), 59.9 and 59.8 (1C), 56.8 and 56.7 (1C), 45.5, 33.8,
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31.9 and 31.20 (1C), 25.5, 23.5 and 22.6 (1C), 19.2 and 19.1
(1C), 18.7 and 18.0 (1C); HRMS (ESI) calcd for C12H22N2NaO3
+
[MNa]+ 265.1523, found 265.1510.
tert-Butyl 2-(((S)-1-methoxy-3-methyl-1-oxobutan-2-yl)carb-
amoyl)piperidine-1-carboxylate 29. Compound 28 (30 mg,
0.12 mmol) and Boc2O (33 mg, 0.15 mmol) were dissolved in
dichloromethane (0.5 mL) and stirred overnight. The mixture
was washed with a saturated aqueous solution of NaHCO3
(2 × 10 mL), a 5% aqueous solution of H3PO4 (2 × 10 mL) and
brine (10 mL). The organic phase was dried over Na2SO4 and
concentrated in vacuo to aﬀord the crude product, which was
purified by FC (9 : 1, n-hexane/ethyl acetate) to give compound
29 (39 mg, 92%) as an inseparable 1 : 1 mixture of diastereo-
isomers. Yellow oil; Rf 0.28 (9 : 1, n-hexane/ethyl acetate);
1H NMR (300 MHz, CDCl3, rotameric mixture of diastereo-
isomers) δ 6.60 (m, br, 0.5H), 6.47 (m, br, 0.5H), 4.78(m, br,
1H), 4.64 (d, br, J = 7.8 and 3.9 Hz, 1H), 4.28–3.89 (m, 1H),
3.72 (s, 3H), 2.85 (t, br, J = 12.7 Hz, 0.7H), 2.77 (m, br, 0.3H),
2.28 (m, br, 1H), 2.17 (m, 1H), 1.71– 1.32 (m, 5H), 1.48 (s, 3H),
1.47 (s, 6H), 0.93 (d, J = 6.8 Hz, 1.7H), 0.92 (d, J = 6.8 Hz, 1.3H),
0.87 (d, J = 6.8 Hz, 1.5H), 0.86 (d, J = 6.8 Hz, 1.5H); 13C NMR
(75 MHz, CDCl3, rotameric mixture of diastereoisomers)
δ 172.4 and 172.1 (1C), 171.3, 161.1, 80.6, 56.9, 52.1, 42.4 and
42.1 (1C), 31.30, 30.9, 28.4 (3C), 25.3, 24.9, 20.5, 19.0, 17.7 and
17.5 (1C); HRMS (ESI) calcd for C17H30N2NaO5
+ [MNa]+
365.2047, found 365.2038.
tert-Butyl 2-(((S)-1-(((S,E)-6-ethoxy-2,5-dimethyl-6-oxohex-4-
en-3-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)carbamoyl)-
piperidine-1-carboxylate 10. LiOH (9 mg, 0.37 mmol) was
added to a suspension of methyl ester 29 (25 mg, 0.07 mmol)
in 50% aqueous methanol (v/v, 2.5 mL). The resulting mixture
was stirred for 18 h at 25 °C, then diluted with water (4 mL)
and extracted with diethyl ether (2 × 4 mL). The aqueous layer
was acidified to pH 2–3 with a 5% aqueous solution of H3PO4
and extracted with EtOAc (3 × 5 mL). The combined organic
layers were dried over Na2SO4 and concentrated in vacuo to
aﬀord the crude acid intermediate (19 mg, 76%), which was
used in the condensation step without purification. HBTU
(15 mg, 40 mmol) was added to a solution of the crude acid
(12 mg, 37 mmol) in dry dichloromethane (2 mL). After
10 min, amine 29 (8 mg, 40 mmol) and DIPEA (8 mL,
44 mmol) in dry dichloromethane (2 mL) were added. The
resulting reaction mixture was stirred for 24 h at 25 °C and
then washed successively with a saturated aqueous solution of
NaHCO3 (two times), water and a 5% aqueous solution of
H3PO4. The resulting organic layer was dried over Na2SO4 and
concentrated in vacuo. The crude residue was purified by FC
(7 : 3, n-hexane/ethyl acetate) to give 10 (12 mg, 62%) as an
inseparable 1 : 1 mixture of diastereoisomers. White amor-
phous solid; Rf (7 : 3, n-hexane/ethyl acetate) 0.29;
1H NMR
(400 MHz, CDCl3, rotameric mixture of diastereoisomers)
δ 6.72–6.59 (m, 1H), 5.12–4.98 (m, 1H), 4.94–4.64 (m, 3H), 4.23
(q, J = 7.1 Hz, 1.2H), 4.22 (q, J = 7.1 Hz, 0.8H), 4.10–3.94 (m,
1H), 3.00 (s, 0.9H), 2.99 (s, 0.3H), 2.98 (s, 0.6H), 2.97 (s, 1.2H),
2.89–2.77 (m, 1H), 2.37–2.20 (m, 1H), 2.08–1.86 (2H), 1.91 (d,
J = 1.4 Hz, 0.9H), 1.90 (d, J = 1.4 Hz, 1.3H), 1.89 (d, J = 1.4 Hz,
0.8H), 1.72–1.40 (m, 5H), 1.60 (s, br, 9H), 1.83 (t, J = 7.1 Hz,
1.8H), 1.82 (t, J = 7.1 Hz, 1.2H), 0.97–0.83 (m, 12H); 13C NMR
(100 MHz, CDCl3, rotameric mixture of diastereoisomers)
δ 172.0 and 171.5 (1C), 171.6 and 171.1 (1C), 167.7, 157.6 and
156.7 (1C), 138.3, 132.9, 80.5, 60.8, 56.9, 56.3, 53.9, 42.6 and
41.2 (1C), 31.2 and 31.1 (1C), 30.4, 30.0, 28.4 (3C), 25.8, 24.9,
20.6, 20.1–17.3 (4C), 14.3, 13.7 and 13.5 (1C); HRMS (ESI)
calcd for C27H47N3NaO6
+ [MNa]+ 532.3357, found 532.3366.
(4S,E)-Ethyl 4-((2S)-N,3-dimethyl-2-(piperidine-2-carbox-
amido)butanamido)-2,5-dimethylhex-2-enoate 30. TFA (0.5 mL)
was added to a solution of compound 10 (128 mg, 0.25 mmol)
in dichloromethane (0.5 mL). The mixture was stirred for 1 h
at 25 °C, and then the solvent was removed in vacuo to give a
residue which was taken with dichloromethane (5 mL) and
washed three times with a 10% aqueous solution of Na2CO3.
The organic layer was dried over Na2SO4 and concentrated
in vacuo to give pure amine 30 as an inseparable 1 : 1 mixture
of diastereoisomers (102 mg, quantitative yield). Colorless oil;
1H NMR (400 MHz, CDCl3, rotameric mixture of diastereoi-
somers) δ 7.70 (d, br, J = 8.2 Hz, 0.25H), 7.48 (d, br, J = 8.4 Hz,
0.5H), 7.36 (d, J = 8.9 Hz, 0.25H), 6.69–6.71 (m, 1H), 5.15–4.92
(m, 1H), 4.86–4.63 (m, 1H), 4.23 (q, J = 7.1 Hz, 2H), 3.69 (m, br,
0.2H), 3.58 (m, br, 0.8H), 3.36–3.23 (m, 1H), 3.03 (s, 1H), 2.99
(s, 2H), 2.89 (m, 1H), 2.36–2.18 (m, 1H), 2.16–1.97 (m, 2H),
1.95–1.86 (m, 1H), 1.90 (s, br, 3H), 1.81 (m, br, 1H), 1.76–1.60
(m, 3H), 1.52 (m, 1H), 1.33 (t, J = 7.1 Hz, 3H), 1.05–0.82 (m,
12H); 13C NMR (100 MHz, CDCl3, rotameric mixture of
diastereoisomers) δ 172.5 and 172.4 (1C), 172.2, 168.4, 138.9
and 138.7 (1C), 133.4, 61.6, 59.6 and 58.8 (1C), 57.8 and 57.5
(1C), 55.1 and 54.9 (1C), 45.3, 31.6 and 31.5 (1C), 31.1, 30.6,
29.4, 25.0 and 24.6 (1C), 23.4 and 23.1 (1C), 20.7–17.7 (4C),
14.9, 14.4; HRMS (ESI) calcd for C22H40N3O4
+ [MH]+ 410.3013,
found 410.3010.
(4S,E)-Ethyl 4-((2S)-2-(1-isopropylpiperidine-2-carboxamido)-
N,3-dimethylbutanamido)-2,5-dimethylhex-2-enoate 11. To a
solution of sodium triacetoxyborohydride (55 mg, 0.26 mmol)
in MeOH (0.5 mL) kept at 0 °C, acetic acid (16 ml, 0.26 mmol),
acetone (19 ml, 0.26 mmol) and a solution of compound 30
(53 mg, 0.13 mmol) in MeOH (0.5 mL) were added. The
mixture was stirred at ambient temperature for 18 h. The reac-
tion was quenched with 0.5 N aqueous sodium potassium tar-
trate (4 mL), then diluted with dichloromethane (4 mL) and
washed with aqueous saturated sodium bicarbonate (3 mL).
The organic layer was dried over Na2SO4 and concentrated
in vacuo to give pure 11 as an inseparable 1 : 1 mixture of dia-
stereoisomers (59 mg, quantitative yield). White amorphous
solid; 1H NMR (400 MHz, CDCl3, rotameric mixture of
diastereoisomers) δ 7.50–7.22 (m, br, 1H), 6.66 (d, br, J =
9.4 Hz, 0.7H), 6.62 (d, br, J = 9.4 Hz, 0.3H), 5.13–4.99 (m, 1H),
4.80–4.62 (m, 1H), 4.22 (q, J = 7.0 Hz, 1.4H), 4.21 (q, J = 7.0 Hz,
0.6H), 3.22–2.92 (m, 1.5H), 2.99 (s, 1H), 2.98 (s, 1H), 2.97 (s,
0.7H), 2.96 (s, 0.3H), 2.85 (m, br, 0.5H), 2.74 (m, br, 1H),
2.38–2.13 (m, br, 1H), 2.13–1.81 (m, br, 2H), 1.91 (d, br, J =
1.2 Hz, 1.5H), 1.90 (d, br, J = 1.2 Hz, 0.9H), 1.87 (d, br, J =
1.2 Hz, 0.6H), 1.76–1.37 (m, br, 4H), 1.82 (t, J = 7.0 Hz, 2.1H),
1.81 (t, J = 7.0 Hz, 0.9H), 1.24 (m, br, 2H), 1.04–0.79 (m, 18H);
Paper Organic & Biomolecular Chemistry
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13C NMR (100 MHz, CDCl3, rotameric mixture of diastereo-
isomers) δ 175.9 and 175.8 (1C), 172.5 and 172.3 (1C), 168.4,
139.1, 133.5 and 133.4 (1C), 65.6 and 64.8 (1C), 61.5, 57.4 and
56.9 (1C), 54.3 and 53.6 (1C), 51.9, 43.2, 31.6, 31.2 and 31.0
(1C), 30.6, 26.0 and 25.5 (1C), 24.2, 23.9, 20.6–18.4 (6C), 14.9,
14.4; HRMS (ESI) calcd for C25H45N3NaO4
+ [MNa]+ 474.3302,
found 474.3318.
(4S,E)-Ethyl 4-((2S)-2-(1-cyclohexylpiperidine-2-carboxamido)-
N,3-dimethylbutanamido)-2,5-dimethylhex-2-enoate 12. To a
solution of sodium triacetoxyborohydride (30 mg, 0.14 mmol)
in MeOH (0.5 mL) kept at 0 °C, acetic acid (9 ml, 0.14 mmol),
cyclohexanone (14 mg, 0.14 mmol) and a solution of com-
pound 30 (30 mg, 0.07 mmol) in MeOH (0.5 mL) were added.
The mixture was stirred at ambient temperature for 18 h. The
reaction was quenched with 0.5 N aqueous sodium potassium
tartrate (2 mL), then diluted with dichloromethane (2 mL) and
washed with aqueous saturated sodium bicarbonate (2 mL).
The organic layer was dried over Na2SO4 and concentrated
in vacuo to give pure 12 as an inseparable 1 : 1 mixture of dia-
stereoisomers (34 mg, quantitative yield). White amorphous
solid; 1H NMR (400 MHz, CDCl3, rotameric mixture of
diastereoisomers) δ 7.52 (m, br, 0.65H), 7.41 (m, br, 0.35H),
6.68–6.59 (m, 1H), 5.15–4.92 (m, br, 1H), 4.87–4.58 (m, 0.7H),
4.58–4.43 (m, 0.3H), 4.20 (q, J = 7.0 Hz, 1.3H), 4.19 (q, J =
7.0 Hz, 0.7H), 3.66–3.51 (m, 2H), 2.96 (s, 2H), 2.88 (s, 1H), 2.34
(t, J = 6.8 Hz, 2H), 2.07–1.49 (m, 15H), 1.37–1.10 (m, 15H),
0.98–0.76 (m, 6H); 13C NMR (100 MHz, CDCl3, mixture of dia-
stereoisomers) δ 171.7 and 171.2 (1C), 167.8 and 167.2 (2C),
138.5, 132.8, 70.3, 60.8, 56.9 and 56.3 (1C), 53.6, 47.5, 42.0, 35.6
(2C), 31.4 and 30.3 (1C), 29.9, 29.8, 29.7, 27.0 (2C), 25.5, 25.0,
24.2, 19.5 and 19.4 (4C), 14.2, 13.8 and 13.7 (1C); HRMS (ESI)
calcd for C28H49N3NaO4
+ [MNa]+ 514.3615, found 514.3608.
Biological studies
Antiproliferative assays. Human T-cell leukemia (Jurkat),
human B-cell leukemia (RS4;11) and human promyelocytic leu-
kemia (HL-60) cells were grown in RPMI-1640 medium (Gibco,
Milano, Italy). Human cervical carcinoma (HeLa), human
colon adenocarcinoma (HT-29), and human breast cancer
(MCF-7) cells were grown in DMEM (Gibco, Milano, Italy).
Both media were supplemented with 115 units per mL of peni-
cillin G (Gibco, Milano, Italy), 115 μg mL−1 of streptomycin
(Invitrogen, Milano, Italy) and 10% fetal bovine serum (Invitro-
gen, Milano, Italy). All cell lines were purchased from ATCC.
Stock solutions (10 mM) of the diﬀerent compounds were
obtained by dissolving them in DMSO. Individual wells of a
96-well tissue culture microtiter plate were inoculated with
100 μL of complete medium containing 8 × 103 cells. The
plates were incubated at 37 °C in a humidified 5% CO2 incuba-
tor for 18 h prior to the experiments. After removal of the
medium, 100 μL of fresh medium containing the test com-
pound at diﬀerent concentrations was added to each well and
incubated at 37 °C for 72 h. Cell viability was assayed by the
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
test and absorbance was measured at 560 nm using a
Victor3™ 1420 Multilabel Counter (PerkinElmer, Waltham,
MA, USA). The GI50 was defined as the compound concen-
tration required to inhibit cell proliferation by 50%.
Eﬀects on tubulin polymerization and on ligand binding to
tubulin. The preparation of electrophoretically homogeneous
bovine brain tubulin was as described previously.26 To evaluate
the eﬀect of the compounds on tubulin assembly in vitro,
varying concentrations of compounds were preincubated with
10 μM bovine brain tubulin in glutamate buﬀer at 30 °C and
then cooled to 0 °C. After the addition of 0.4 mM GTP, the
mixtures were transferred to 0 °C cuvettes in a recording
spectrophotometer and warmed to 30 °C. Tubulin assembly
was followed turbidimetrically at 350 nm. The IC50 is defined
as the compound concentration that inhibited the extent of
assembly by 50% after a 20 min incubation. The assay was
described previously in detail.27 The ability of the test com-
pounds to inhibit [3H]vinblastine (from Perkin-Elmer, Boston
MA), [3H]dolastatin 10 (supplied by the Drug Synthesis and
Chemistry Branch, Developmental Therapeutics Program,
National Cancer Institute, Gaithersburg MD) and [3H]hali-
chondrin B (custom synthesized28) binding to tubulin was
measured as described previously by centrifugal gel filtration
chromatography.28 Briefly, experiments were performed in
0.1 M 4-morpholinethanesulfonate (pH 6.9 in 1 M stock solu-
tion adjusted with NaOH)–0.5 mM MgCl2 containing 10 µM
tubulin (1.0 mg ml−1), 10 µM radiolabeled ligand, and inhibi-
tors at diﬀerent concentrations. The reaction volume was
0.3 mL and the incubation time was 15 min at rt (around
20 °C). Ligands were mixed prior to tubulin addition. Dupli-
cate aliquots of each reaction mixture were applied to syringe
columns of Sephadex G-50 (superfine) swollen in 0.1 M Mes–
0.5 mM MgCl2 (pH = 6.9).
Flow cytometric analysis of cell cycle distribution. 5 × 105
HeLa cells in exponential growth were treated with diﬀerent
concentrations of the test compounds for 24 h. After the incu-
bation period, the cells were collected, centrifuged and fixed
with ice-cold ethanol (70%). The cells were then treated with
lysis buﬀer containing RNAse A and 0.1% Triton X-100, and
then stained with propidium iodide. The samples were ana-
lyzed on a Cytomic FC500 flow cytometer (Beckman Coulter).
DNA histograms were analyzed using MultiCycle® for
Windows (Phoenix Flow Systems).
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